Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...
Investor's Business Daily on MSN1 天
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...
PharmiWeb7 天
Understanding CAR T-Cell Therapy: A Revolutionary Approach to Cancer Treatment
CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...
Nature1 年
Rapa’s epigenetic reprogramming creates T cell therapies for solid tumors and ...
thereby paving the path for dedicated phase 2b trials in these cancer types, with more indications being tested. Given zero CRS toxicity treating patients in an outpatient setting, and substantial ...
Fred Hutch3 年
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
At Fred Hutch Cancer Center and University of Washington Medical Center, we have an experienced team that provides CRS-HIPEC. Many of our patients receive all their cancer care through Fred Hutch and ...